X4 Pharmaceuticals (XFOR) Total Current Liabilities (2017 - 2025)

X4 Pharmaceuticals' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $25.8 million for Q4 2025.

• Quarterly Total Current Liabilities fell 21.66% year-over-year to $25.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $25.8 million (down 21.66% YoY) and the FY2025 annual result came in at $25.8 million, down 21.66% from the prior year.
• Total Current Liabilities was $25.8 million for Q4 2025 at X4 Pharmaceuticals, up from $23.5 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $32.9 million in Q4 2024 and bottomed at $13.1 million in Q2 2021.
• A 5-year average of $22.3 million and a median of $22.9 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 117.0% — and 2025, when it decreased 21.66%.
• X4 Pharmaceuticals' Total Current Liabilities stood at $14.0 million in 2021, then soared by 59.2% to $22.3 million in 2022, then advanced by 2.41% to $22.9 million in 2023, then soared by 43.81% to $32.9 million in 2024, then dropped by 21.66% to $25.8 million in 2025.
• Business Quant data shows XFOR's Total Current Liabilities at $25.8 million in Q4 2025, $23.5 million in Q3 2025, and $22.9 million in Q2 2025.